This segment focuses on the research, development, and clinical trials of natural killer (NK) cell-based therapies for various cancers. NantKwest developed and tested haNK (highly activated NK) cells, including those targeted to specific tumor antigens. Research and development activities include identifying and validating new targets, engineering NK cells for enhanced efficacy, and conducting clinical trials to evaluate safety and efficacy in different cancer types. Technologies used include cell culture, genetic engineering, and advanced immunological assays. The therapeutic areas covered include solid tumors such as pancreatic cancer, and bladder cancer. The patient impact is aimed at improving survival rates and quality of life for cancer patients. Market positioning is as a pioneer in NK cell therapy, with a focus on off-the-shelf therapies. Future opportunities include expanding the pipeline to other cancer indications and developing combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships and collaborations include agreements with ImmunityBio and the National Cancer Institute.